Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.

ABSTRACT:

Objectives

Our objective was to compare prostate cancer detection rates between patients undergoing serum prostate-specific antigen (PSA) vs magnetic resonance imaging (MRI) for prostate cancer screening.

Design

Phase III open-label randomised controlled trial.

Setting

Single tertiary cancer centre in Toronto, Canada.

Participants

Men 50 years of age and older with no history of PSA screening for ≥3 years, a negative digital rectal exam and no prior prostate biopsy.

Interventions

Patients were recommended to undergo a prostate biopsy if their PSA was ≥2.6 ng/mL (PSA arm) or if they had a PIRADS score of 4 or 5 (MRI arm). Patients underwent an end-of-study PSA in the MRI arm.

Primary and secondary outcome measures

Adenocarcinoma on prostate biopsy.

SUBMITTER: Nam R 

PROVIDER: S-EPMC9644313 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature